Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Junyu Tong in
Google Scholar
PubMed
Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
Search for other papers by Maomei Ruan in
Google Scholar
PubMed
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Search for other papers by Hao Fu in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Search for other papers by Qiong Luo in
Google Scholar
PubMed
Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Zhiyan Liu in
Google Scholar
PubMed
Search for other papers by Zhongwei Lv in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
thyroid carcinoma derived from follicular epithelial cells, poorly differentiated thyroid carcinoma (PDTC) ranks between DTC and ATC regarding the degree of differentiation ( 4 ). PDTC was initially proposed as a separate entity by Sakamoto et al. in
Search for other papers by João Roque in
Google Scholar
PubMed
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Tiago Nunes Silva in
Google Scholar
PubMed
Search for other papers by Catarina Regala in
Google Scholar
PubMed
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Introduction The term poorly differentiated thyroid carcinoma (PDTC) was first introduced by Granner and colleagues in 1963, although it was only recognized as a distinct entity by the World Health Organization in 2004 ( 1 , 2 ). In 2006, the
Search for other papers by Tiago Nunes da Silva in
Google Scholar
PubMed
Search for other papers by Edward Limbert in
Google Scholar
PubMed
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Introduction Poorly differentiated thyroid carcinoma (PDTC) is a rare type of thyroid cancer accounting for < 6% of all thyroid malignancies [ 1 ]. Nevertheless, it is the second cause of death from follicular cell-derived thyroid cancer after
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by David Viola in
Google Scholar
PubMed
Search for other papers by Valeria Bottici in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Luciana Puleo in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Search for other papers by Alessandro Ribechini in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
patients were adults with locally advanced or metastatic RAI-R DTC or poorly differentiated thyroid cancer (PDTC). Patients enrolled in clinical trials had to have satisfied the enrolling criteria of the specific clinical trials [ 2 , 14 ]. For enrollment
Search for other papers by Pepijn van Houten in
Google Scholar
PubMed
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
Search for other papers by James Nagarajah in
Google Scholar
PubMed
Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed
Search for other papers by Martin Jaeger in
Google Scholar
PubMed
Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed
Search for other papers by Johannes W Smit in
Google Scholar
PubMed
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed
-3379) Pilot trial 5 weeks PTC, PDTC BRAF V600E 6 5/6 Leboulleux et al. ( 9 ) Dabrafenib + trametinib Phase II trial 5 weeks PTC, PDTC BRAF V600E 21 20/21 Rothenberg et al. ( 11 ) Dabrafenib Pilot trial 4
Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Joachim N Nilsson in
Google Scholar
PubMed
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Jonathan Siikanen in
Google Scholar
PubMed
Search for other papers by Vincenzo Condello in
Google Scholar
PubMed
Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Kenbugul Jatta in
Google Scholar
PubMed
Search for other papers by Ravi Saini in
Google Scholar
PubMed
Stockholms Sjukhem Foundation's Research and Development Department, Stockholm, Sweden
Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Search for other papers by Christel Hedman in
Google Scholar
PubMed
Department of Breast, Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Catharina Ihre Lundgren in
Google Scholar
PubMed
Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by C Christofer Juhlin in
Google Scholar
PubMed
and 2021, were analysed. The data included primary tumour samples of PTC (21 patients), of differentiated high-grade thyroid cancer (DHGTC; 1 patient), of poorly differentiated thyroid cancer (PDTC; 3 patients) and lymph node metastases of PTC (11
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
/male 65/65 FTC M1 a /IVb LN, trachea, lung, sternum 24 0 SD 26 12 3 2 (ARB, BB) #8/female 63/74 PDTC T3NXM0/II LN, lung 20 0 PR 38 15 2 3 (CCB, ARB, D) #9/male 50/66 PTC T2NXMX/I LN, lung
Center for Health Technology and Services Research (CINTESIS), Porto, Portugal
Search for other papers by Claudia Matta-Coelho in
Google Scholar
PubMed
Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Search for other papers by Helena Vilar in
Google Scholar
PubMed
Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
treatment (surgery plus RAIT), Tg levels under levothyroxine suppression were elevated in 73 of 75 patients, and the remaining 2 patients had a serum Tg < 0.2 ng/mL. One was a patient with a poorly differentiated thyroid carcinoma (PDTC), negative anti
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
DTC or poorly differentiated thyroid carcinoma (PDTC) (Table 1 ). Of these, a total of 8 patients were excluded from the analysis for the following reasons: 6 because they did not complete more than 2 months of therapy (5 died as a consequence of
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Jan Smit in
Google Scholar
PubMed
tumours are regarded as a separate group. The HC carcinomas are divided into minimally invasive, encapsulated angioinvasive, and widely invasive subtypes, following the same criteria as those applied to FTC. Poorly differentiated thyroid carcinoma (PDTC